Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is frequently performed in patients with hematological malignancy. However, the pulmonary function of such patients is often decreased after allo-HSCT. The aim of this study was to clarify the risk factors for decreased pulmonary function after allo-HSCT. The decreased pulmonary function was defined as %FEV1.0, where %FEV1.0 decreased by 10% or more and %FEV1.0 was less than 80% after transplantation. Fourteen clinical factors including sex, body mass index (BMI), blood disease indicated for allo-HSCT, hematopoietic cell transplantation-specific comorbidity index, types of allo-HSCT, myeloablative treatment, total body irradiation, match of blood type, HLA type and sex, existence of consanguinity, antibodies of cytomegalovirus in donors and prophylactic measure of GVHD were analyzed to determine their relationship with decreased pulmonary function after allo-HSCT by univariate and multivariate analyses. The multivariate analysis showed that BMI < 18.5 kg/m2, acute lymphatic leukemia, and myeloablative treatment were significant risk factors for the decreased pulmonary function after allo-HSCT. Patients with these factors should be closely followed-up after allo-HSCT.
